治療用ワクチン市場：ワクチンタイプ別、適応疾患別、投与法別、エンドユーザー別-2025-2030年の世界予測

治療用ワクチン市場は、2023年に300億8,000万米ドルと評価され、2024年には330億5,000万米ドルに達すると予測され、CAGR 10.35%で成長し、2030年には599億5,000万米ドルに達すると予測されています。

治療用ワクチンは、従来のワクチンとは異なり、病気を予防するのではなく、既存の病気を治療するように設計された、ヘルスケア産業における変革的なセグメントです。特定の病原体やがん細胞を標的として排除するために、身体の免疫反応を利用することで機能します。治療用ワクチンの必要性は、がん、自己免疫疾患、感染症などの慢性疾患や生命を脅かす疾患に対する、より効果的で的を絞った治療の必要性から生じています。これらのワクチンは、がん、感染症、さまざまな慢性疾患に応用されており、エンドユーザーはヘルスケアプロバイダー、研究機関、製薬会社など多岐にわたります。治療用ワクチン市場は、バイオテクノロジーの進歩、研究開発投資の増加、世界の慢性疾患罹患率の上昇を背景に、大きく成長する見込みです。個別化医療、バイオ医薬品の普及、ワクチン開発におけるAIと機械学習の統合などの要因が、革新と進歩のための肥沃な土壌を作り出しています。同市場における新たな機会としては、新たなワクチン製剤の探索、併用療法、他の課題疾患への適用範囲の拡大などが挙げられます。しかし、開発コストの高さ、規制上の厳しいハードル、高価格設定による市場浸透の制限といった課題は、市場の成長に影響を与えています。さらに、臨床試験における製造の複雑さや安全性への懸念が大きなボトルネックとなっています。技術革新と事業成長を促進するためには、次世代シーケンシング、バイオマーカー探索、新しいアジュバント技術の開発に重点を置くべきです。研究開発加速のための共同パートナーシップ、規制プロセスの合理化、政府・非政府組織からの資金調達の強化に重点を置くことが重要であろう。全体として、市場は急速な進歩と競合情勢を特徴としています。既存の課題を効果的に乗り切りながら技術的変化に適応できる企業は、際立った優位性と大きな成長の可能性を手にすることができると思われます。

市場力学：急速に進化する治療用ワクチン市場の主要市場インサイトを公開

治療用ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患や感染症などの疾病の有病率の上昇
  • 標的疾患に対する生物製剤や医薬品への需要の高まり
  • ワクチン開発に対する政府資金の増加
• 市場抑制要因
  • 治療用ワクチンに関連する副作用
  • ワクチンの承認に関する政府の厳しい規制
• 市場機会
  • ワクチン接種を推進するための政府および民間組織によるイニシアチブの高まり
  • ペプチドベースの治療用ワクチンや肺炎球菌ワクチンなど新規ワクチンのイントロダクション
  • 研究開発活動の活発化とパイプラインでのワクチン開発
• 市場の課題
  • ワクチン製造のための臨床試験の遅滞
  • 治療用ワクチンの開発に伴う高コスト

ポーターの5つの力治療用ワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、治療用ワクチン市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：治療用ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、治療用ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析治療用ワクチン市場における競合情勢の把握

治療用ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス治療用ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、治療用ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨治療用ワクチン市場における成功への道筋を描く

治療用ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患や感染症などの疾病の罹患率の上昇
    • 標的疾患に対する生物製剤および医薬品の需要増加
    • ワクチン開発への政府資金の増加
  • 抑制要因
    • 治療用ワクチンに関連する副作用
    • ワクチンの承認に関する厳格な政府規制
  • 機会
    • ワクチン接種を推進する政府や民間団体の取り組みが増加
    • ペプチドベースの治療ワクチンや肺炎球菌ワクチンなどの新しいワクチンのイントロダクション
    • 研究開発活動の増加とパイプライン内のワクチン開発
  • 課題
    • 一部のワクチン製造のための臨床試験の処理が遅い
    • 治療用ワクチンの開発に伴う高コスト
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 治療用ワクチン市場ワクチンの種類別

• 自己免疫疾患ワクチン
• 慢性疾患ワクチン
• 感染症ワクチン
• 神経疾患ワクチン

第7章 治療用ワクチン市場：疾患適応症別

• デング熱
• DTP
• 肝炎
• ヒトパピローマウイルス
• インフルエンザ
• 髄膜炎菌感染症
• MMR
• 肺炎球菌感染症
• ポリオ
• 水痘

第8章 治療用ワクチン市場管理別

• 筋肉内および皮下投与
• 経口投与

第9章 治療用ワクチン市場：エンドユーザー別

• 大人
• 小児科

第10章 南北アメリカの治療用ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の治療用ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの治療用ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AFFiRiS AG
• Agenus Inc.
• Argos Therapeutics Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Bavarian Nordic A/S
• Celldex Therapeutics, Inc.
• CSL Limited
• Emergent Biosolutions, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.

LIST OF FIGURES

• FIGURE 1. THERAPEUTIC VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. THERAPEUTIC VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. THERAPEUTIC VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. THERAPEUTIC VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTO-IMMUNE DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CHRONIC DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENGUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HUMAN PAPILLOMA VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 65. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 138. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 154. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 158. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 198. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The Therapeutic Vaccines Market was valued at USD 30.08 billion in 2023, expected to reach USD 33.05 billion in 2024, and is projected to grow at a CAGR of 10.35%, to USD 59.95 billion by 2030.

Therapeutic vaccines represent a transformative segment in the healthcare industry, designed to treat existing diseases rather than prevent them, unlike traditional vaccines. They function by harnessing the body's immune response to target and eliminate specific pathogens or cancerous cells. The necessity for therapeutic vaccines arises from the need for more effective and targeted treatments for chronic and life-threatening diseases such as cancer, autoimmune disorders, and infectious diseases where traditional therapeutic approaches prove inadequate or detrimental. These vaccines find applications across oncology, infectious diseases, and various chronic conditions, with end-users spanning healthcare providers, research organizations, and pharmaceutical companies. The market for therapeutic vaccines is poised for significant growth, driven by advancements in biotechnology, increasing research and development investments, and rising incidences of chronic diseases globally. Factors such as personalized medicine, the proliferation of biopharmaceuticals, and the integration of AI and machine learning in vaccine development create a fertile ground for innovation and progress. Emerging opportunities in the market include exploring new vaccine formulations, combination therapies, and expanding the application scope to other challenging diseases. However, challenges such as high developmental costs, stringent regulatory hurdles, and limited market penetration due to high pricing affect market growth. Additionally, manufacturing complexities and safety concerns in clinical trials pose significant bottlenecks. To foster innovation and business growth, focus should be directed towards next-generation sequencing, biomarker discovery, and the development of new adjuvant technologies. A strong emphasis on collaborative partnerships for accelerated R&D, streamlined regulatory processes, and increased funding from governmental and non-governmental entities will be critical. Overall, the market is characterized by rapid advancements and a competitive landscape. Companies that can adapt to technological changes while effectively navigating the existing challenges will have a distinctive edge and significant growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Vaccines Market

The Therapeutic Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence rate of diseases such as chronic and infectious diseases
  • Rising demand for biologics and drugs for targeted diseases
  • Growing government funding for vaccine development
• Market Restraints
  • Side effects associated with therapeutic vaccines
  • Stringent government regulations for the approval of vaccines
• Market Opportunities
  • Growing initiatives from government and private organizations to advance vaccination
  • Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
  • Rising R&D activities and vaccines developments in the pipeline
• Market Challenges
  • Slow processing of clinical trials for the production of some vaccine
  • High cost associated with the development of the therapeutic vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Vaccines Market

A detailed market share analysis in the Therapeutic Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Therapeutic Vaccines Market

A strategic analysis of the Therapeutic Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Vaccines Market, highlighting leading vendors and their innovative profiles. These include AFFiRiS AG, Agenus Inc., Argos Therapeutics Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Celldex Therapeutics, Inc., CSL Limited, Emergent Biosolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., and Serum Institute of India Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Vaccines Type, market is studied across Auto-Immune Diseases Vaccines, Chronic Disease Vaccines, Infectious Diseases Vaccines, and Neurological Disease Vaccines.
• Based on Disease Indication, market is studied across Dengue, DTP, Hepatitis, Human Papilloma Virus, Influenza, Meningococcal Disease, MMR, Pneumococcal Disease, Polio, and Varicella.
• Based on Administration, market is studied across Intramuscular & Subcutaneous Administration and Oral Administration.
• Based on End-User, market is studied across Adults and Pediatrics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence rate of diseases such as chronic and infectious diseases
    • 5.1.1.2. Rising demand for biologics and drugs for targeted diseases
    • 5.1.1.3. Growing government funding for vaccine development
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with therapeutic vaccines
    • 5.1.2.2. Stringent government regulations for the approval of vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing initiatives from government and private organizations to advance vaccination
    • 5.1.3.2. Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
    • 5.1.3.3. Rising R&D activities and vaccines developments in the pipeline
  • 5.1.4. Challenges
    • 5.1.4.1. Slow processing of clinical trials for the production of some vaccine
    • 5.1.4.2. High cost associated with the development of the therapeutic vaccines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Therapeutic Vaccines Market, by Vaccines Type

• 6.1. Introduction
• 6.2. Auto-Immune Diseases Vaccines
• 6.3. Chronic Disease Vaccines
• 6.4. Infectious Diseases Vaccines
• 6.5. Neurological Disease Vaccines

7. Therapeutic Vaccines Market, by Disease Indication

• 7.1. Introduction
• 7.2. Dengue
• 7.3. DTP
• 7.4. Hepatitis
• 7.5. Human Papilloma Virus
• 7.6. Influenza
• 7.7. Meningococcal Disease
• 7.8. MMR
• 7.9. Pneumococcal Disease
• 7.10. Polio
• 7.11. Varicella

8. Therapeutic Vaccines Market, by Administration

• 8.1. Introduction
• 8.2. Intramuscular & Subcutaneous Administration
• 8.3. Oral Administration

9. Therapeutic Vaccines Market, by End-User

• 9.1. Introduction
• 9.2. Adults
• 9.3. Pediatrics

10. Americas Therapeutic Vaccines Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Therapeutic Vaccines Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Vaccines Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AFFiRiS AG
• 2. Agenus Inc.
• 3. Argos Therapeutics Inc.
• 4. Astellas Pharma, Inc.
• 5. AstraZeneca PLC
• 6. Bavarian Nordic A/S
• 7. Celldex Therapeutics, Inc.
• 8. CSL Limited
• 9. Emergent Biosolutions, Inc.
• 10. GlaxoSmithKline PLC
• 11. Johnson & Johnson Services, Inc.
• 12. Merck & Co., Inc.
• 13. Pfizer, Inc.
• 14. Sanofi S.A.
• 15. Serum Institute of India Pvt. Ltd.